JP2015536941A5 - - Google Patents

Download PDF

Info

Publication number
JP2015536941A5
JP2015536941A5 JP2015540228A JP2015540228A JP2015536941A5 JP 2015536941 A5 JP2015536941 A5 JP 2015536941A5 JP 2015540228 A JP2015540228 A JP 2015540228A JP 2015540228 A JP2015540228 A JP 2015540228A JP 2015536941 A5 JP2015536941 A5 JP 2015536941A5
Authority
JP
Japan
Prior art keywords
administered
combination
day
tki
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015540228A
Other languages
English (en)
Japanese (ja)
Other versions
JP6453224B2 (ja
JP2015536941A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/002583 external-priority patent/WO2014068397A1/en
Publication of JP2015536941A publication Critical patent/JP2015536941A/ja
Publication of JP2015536941A5 publication Critical patent/JP2015536941A5/ja
Application granted granted Critical
Publication of JP6453224B2 publication Critical patent/JP6453224B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015540228A 2012-11-05 2013-11-05 インビボで血液がんの幹細胞を排除するため、および血液がんの再発を防ぐための、チロシンキナーゼ阻害剤のような抗がん剤と、好ましくはチアゾリジンジオンであるｓｔａｔ５アンタゴニストとの組み合わせ Active JP6453224B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261722633P 2012-11-05 2012-11-05
US61/722,633 2012-11-05
US201361794367P 2013-03-15 2013-03-15
US61/794,367 2013-03-15
PCT/IB2013/002583 WO2014068397A1 (en) 2012-11-05 2013-11-05 Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse

Publications (3)

Publication Number Publication Date
JP2015536941A JP2015536941A (ja) 2015-12-24
JP2015536941A5 true JP2015536941A5 (https=) 2016-12-22
JP6453224B2 JP6453224B2 (ja) 2019-01-16

Family

ID=49998588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015540228A Active JP6453224B2 (ja) 2012-11-05 2013-11-05 インビボで血液がんの幹細胞を排除するため、および血液がんの再発を防ぐための、チロシンキナーゼ阻害剤のような抗がん剤と、好ましくはチアゾリジンジオンであるｓｔａｔ５アンタゴニストとの組み合わせ

Country Status (9)

Country Link
US (1) US9623015B2 (https=)
EP (1) EP2914250B1 (https=)
JP (1) JP6453224B2 (https=)
AU (1) AU2013340478B2 (https=)
CA (1) CA2890086C (https=)
DK (1) DK2914250T3 (https=)
ES (1) ES2668310T3 (https=)
HK (1) HK1214760A1 (https=)
WO (1) WO2014068397A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104398520B (zh) * 2014-11-04 2017-01-18 复旦大学附属上海市第五人民医院 Ruxolitinib在制备治疗M2型急性髓系白血病药物中的应用
JP6775226B2 (ja) * 2016-06-30 2020-10-28 国立大学法人広島大学 抗癌剤作用増強物質およびそれを備えた抗癌剤キット
CN107674914A (zh) * 2016-08-02 2018-02-09 熊术道 一步单管法定量rt‑pcr检测慢性髓系白血病bcr‑abl1基因的表达量
EP4054579A1 (en) * 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
GB202210503D0 (en) * 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS58118577A (ja) 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1986007056A1 (en) 1985-05-21 1986-12-04 Pfizer Inc. Hypoglycemic thiazolidinediones
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
US4873255A (en) 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
FI91869C (fi) 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
EP0295828A1 (en) 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
SG59988A1 (en) 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
US5521201A (en) 1987-09-04 1996-05-28 Beecham Group P.L.C. Method for treatment of atherosclerosis
US5232925A (en) 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5260445A (en) 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
US5194443A (en) 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5120754A (en) 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5223522A (en) 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008650A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
US5306822A (en) 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
US4897405A (en) 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919434D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5143928A (en) 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
JPH0469383A (ja) 1990-07-06 1992-03-04 Yamanouchi Pharmaceut Co Ltd 置換チアゾリジン誘導体
GB9017218D0 (en) 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
US5498621A (en) 1992-05-01 1996-03-12 Pfizer Inc. Oxazolidinedione hypoglycemic agents
WO1994001433A1 (fr) 1992-07-13 1994-01-20 Japan Tobacco Inc. Nouveau compose de thiazolidinedione et son utilisation
EP0915090A1 (en) 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
US5521202A (en) 1993-04-07 1996-05-28 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivatives and pharmaceutical compositions containing the same
DE69405902T2 (de) 1993-04-16 1998-01-29 Central Glass Co Ltd Glasscheibe mit reflexvermindernder Beschichtung und Kombinationselement eines Einspiegelungssichtgerätesystems
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
WO1995018533A1 (en) 1994-01-04 1995-07-13 The Trustees Of The University Of Pennsylvania Methods and compounds affecting adipocyte differentiation and obesity
US5480896A (en) 1994-01-27 1996-01-02 American Home Products Corporation Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents
US5468762A (en) 1994-05-18 1995-11-21 American Home Products Corporation Azolidinediones as antihyperglycemic agents
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
EP1410799B1 (en) 1996-12-11 2010-03-31 Dana-Farber Cancer Institute, Inc. Methods and pharmaceutical compositions for inhibiting tumour cell growth
AU5811298A (en) 1996-12-31 1998-07-31 Salk Institute For Biological Studies, The Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
NZ517993A (en) 1999-08-31 2004-03-26 Incyte San Diego Inc Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
US7045523B2 (en) 2001-10-18 2006-05-16 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and telomerase inhibitor
WO2006111365A1 (de) 2005-04-19 2006-10-26 Cedes Ag Vorrichtung zur steuerung eines angetriebenen bewegungselements, zum beispiel einer tür
WO2008029827A1 (fr) 2006-09-07 2008-03-13 Tama-Tlo Ltd. PROCÉDÉ DE PRODUCTION DE CRISTAL D'AlN

Similar Documents

Publication Publication Date Title
Figlin et al. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors
Lazăr et al. New advances in targeted gastric cancer treatment
Jeong et al. US FDA approved oral kinase inhibitors for the treatment of malignancies
Bisi et al. Preclinical characterization of G1T28: a novel CDK4/6 inhibitor for reduction of chemotherapy-induced myelosuppression
Nikolaou et al. Melanoma: new insights and new therapies
Manic et al. Chloroquine and hydroxychloroquine for cancer therapy
CN102089007B (zh) (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品
Goldman et al. Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
DK2558095T3 (en) ORGANIC RELATIONSHIP FOR USE IN TREATMENT OF DELIVERY CANCER
Minguet et al. Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives
US20230181565A1 (en) Crenolanib combination therapy
JP2015536941A5 (https=)
Izzedine Anti‐VEGF cancer therapy in nephrology practice
HRP20160447T1 (hr) Spojevi benzensulfonamid-tiazola i benzensulfonamid-oksazola
JP2017502013A5 (https=)
AU2003282892A1 (en) Synergistic methods and compositions for treating cancer
JP2022044767A (ja) 癌を処置する方法
WO2017043633A1 (ja) ＩＫＺＦ１変異を有するフィラデルフィア染色体陽性（Ｐｈ＋）急性リンパ性白血病（ＡＬＬ）の治療薬又は治療方法
JP2014525454A5 (https=)
Fishman et al. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma
Nukatsuka et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with oxaliplatin on human colorectal and gastric cancer xenografts
JP2019525948A5 (https=)
Songdej et al. GIST treatment options after tyrosine kinase inhibitors
CN105338980A (zh) 药物组合
CN102958518A (zh) 磷脂酰肌醇3-激酶抑制剂和抗糖尿病化合物的组合